Tenet Healthcare (NYSE:THC - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Sunday.
A number of other equities analysts have also issued reports on the stock. Robert W. Baird reaffirmed a "neutral" rating and set a $137.00 target price (down previously from $153.00) on shares of Tenet Healthcare in a research report on Tuesday, April 15th. Bank of America increased their target price on Tenet Healthcare from $165.00 to $180.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Barclays increased their price objective on Tenet Healthcare from $171.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, June 2nd. TD Cowen began coverage on Tenet Healthcare in a report on Wednesday, February 26th. They set a "buy" rating and a $175.00 price target for the company. Finally, Wells Fargo & Company raised Tenet Healthcare from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $150.00 to $195.00 in a report on Thursday, May 29th. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $182.24.
View Our Latest Analysis on THC
Tenet Healthcare Trading Down 0.8%
Tenet Healthcare stock opened at $164.23 on Friday. The company has a market cap of $15.25 billion, a P/E ratio of 5.10, a PEG ratio of 1.02 and a beta of 1.65. The company has a debt-to-equity ratio of 2.25, a quick ratio of 1.70 and a current ratio of 1.78. The firm's 50-day moving average is $148.09 and its 200-day moving average is $137.62. Tenet Healthcare has a 1 year low of $109.82 and a 1 year high of $174.14.
Tenet Healthcare (NYSE:THC - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $4.36 earnings per share for the quarter, beating the consensus estimate of $3.11 by $1.25. The company had revenue of $5.22 billion during the quarter, compared to analyst estimates of $5.15 billion. Tenet Healthcare had a net margin of 15.48% and a return on equity of 21.88%. The business's revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.22 EPS. On average, equities analysts expect that Tenet Healthcare will post 12.24 earnings per share for the current year.
Insider Activity
In related news, Director J Robert Kerrey sold 5,001 shares of the stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $148.50, for a total transaction of $742,648.50. Following the sale, the director now owns 22,377 shares in the company, valued at $3,322,984.50. This represents a 18.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard W. Fisher sold 836 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $173.16, for a total transaction of $144,761.76. Following the completion of the transaction, the director now owns 11,292 shares of the company's stock, valued at approximately $1,955,322.72. This trade represents a 6.89% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,121 shares of company stock worth $8,846,305. Corporate insiders own 0.81% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in THC. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Tenet Healthcare in the 1st quarter valued at approximately $26,000. Wayfinding Financial LLC purchased a new stake in Tenet Healthcare in the 1st quarter worth approximately $28,000. SVB Wealth LLC purchased a new stake in Tenet Healthcare in the 1st quarter worth approximately $30,000. Colonial Trust Co SC lifted its position in Tenet Healthcare by 85.7% in the 4th quarter. Colonial Trust Co SC now owns 247 shares of the company's stock worth $31,000 after buying an additional 114 shares in the last quarter. Finally, N.E.W. Advisory Services LLC purchased a new stake in Tenet Healthcare in the 1st quarter worth approximately $31,000. 95.44% of the stock is currently owned by institutional investors.
About Tenet Healthcare
(
Get Free Report)
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tenet Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenet Healthcare wasn't on the list.
While Tenet Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.